BRAF and neoplasm: To determine whether the dysregulation of miRNA expression in PTC patients was associated with clinicopathological features, we further analyzed the expression of miR-124-3p, miR-9-3p and miR-196b-5p in different subgroups divided by age, gender, tumor-related pathological characteristics or BRAF gene mutation, which is the most important proto-oncogene in PTC.